These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 28441068)

  • 1. A Controlled, Randomized Double-Blind Study to Evaluate the Safety and Efficacy of Chitosan-N-Acetylcysteine for the Treatment of Dry Eye Syndrome.
    Schmidl D; Werkmeister R; Kaya S; Unterhuber A; Witkowska KJ; Baumgartner R; Höller S; O'Rourke M; Peterson W; Wolter A; Prinz M; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2017 Jun; 33(5):375-382. PubMed ID: 28441068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tear film thickness after treatment with artificial tears in patients with moderate dry eye disease.
    Schmidl D; Schmetterer L; Witkowska KJ; Unterhuber A; dos Santos VA; Kaya S; Nepp J; Baar C; Rosner P; Werkmeister RM; Garhofer G
    Cornea; 2015 Apr; 34(4):421-6. PubMed ID: 25651494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of different lubricant eye gels on tear film thickness as measured with ultrahigh-resolution optical coherence tomography.
    Wozniak PA; Schmidl D; Bata AM; Fondi K; Witkowska KJ; Aranha Dos Santos V; Baar C; Room KI; Nepp J; Baumgartner I; Popa-Cherecheanu A; Garhöfer G; Werkmeister RM; Schmetterer L
    Acta Ophthalmol; 2017 Jun; 95(4):e307-e313. PubMed ID: 27989018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of Perfluorohexyloctane Eye Drops on Tear Film Thickness in Patients with Mild to Moderate Dry Eye Disease: A Randomized Controlled Clinical Trial.
    Schmidl D; Bata AM; Szegedi S; Aranha Dos Santos V; Stegmann H; Fondi K; Krösser S; Werkmeister RM; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):154-161. PubMed ID: 31895638
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of chitosan-N-acetylcysteine conjugate in a mouse model of botulinum toxin B-induced dry eye.
    Hongyok T; Chae JJ; Shin YJ; Na D; Li L; Chuck RS
    Arch Ophthalmol; 2009 Apr; 127(4):525-32. PubMed ID: 19365035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Single Instillation of Two Hyaluronic Acid-Based Topical Lubricants on Tear Film Thickness in Patients with Dry Eye Syndrome.
    Szegedi S; Scheschy U; Schmidl D; Aranha Dos Santos V; Stegmann H; Adzhemian N; Fondi K; Bata AM; Werkmeister RM; Couderc C; Schmetterer L; Garhofer G
    J Ocul Pharmacol Ther; 2018 Nov; 34(9):605-611. PubMed ID: 30325687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of moderate-to-severe dry eye disease using chitosan-N-acetylcysteine (Lacrimera®) eye drops: a retrospective case series.
    Nepp J; Knoetzl W; Prinz A; Hoeller S; Prinz M
    Int Ophthalmol; 2020 Jun; 40(6):1547-1552. PubMed ID: 32124131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hyaluronic acid on tear film thickness as assessed with ultra-high resolution optical coherence tomography.
    Kaya S; Schmidl D; Schmetterer L; Witkowska KJ; Unterhuber A; Aranha Dos Santos V; Baar C; Garhöfer G; Werkmeister RM
    Acta Ophthalmol; 2015 Aug; 93(5):439-443. PubMed ID: 25601227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early results on the use of chitosan-N-acetylcysteine (Lacrimera
    Messina M; Dua HS
    Int Ophthalmol; 2019 Mar; 39(3):693-696. PubMed ID: 29549486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The association between subjective and objective parameters for the assessment of dry-eye syndrome.
    Schmidl D; Witkowska KJ; Kaya S; Baar C; Faatz H; Nepp J; Unterhuber A; Werkmeister RM; Garhofer G; Schmetterer L
    Invest Ophthalmol Vis Sci; 2015 Feb; 56(3):1467-72. PubMed ID: 25650419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
    Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
    Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a Multicenter, Randomized, Double-Masked, Placebo-Controlled Clinical Study of the Efficacy and Safety of Visomitin Eye Drops in Patients with Dry Eye Syndrome.
    Brzheskiy VV; Efimova EL; Vorontsova TN; Alekseev VN; Gusarevich OG; Shaidurova KN; Ryabtseva AA; Andryukhina OM; Kamenskikh TG; Sumarokova ES; Miljudin ES; Egorov EA; Lebedev OI; Surov AV; Korol AR; Nasinnyk IO; Bezditko PA; Muzhychuk OP; Vygodin VA; Yani EV; Savchenko AY; Karger EM; Fedorkin ON; Mironov AN; Ostapenko V; Popeko NA; Skulachev VP; Skulachev MV
    Adv Ther; 2015 Dec; 32(12):1263-79. PubMed ID: 26660938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
    Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
    Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops.
    Ousler GW; Michaelson C; Christensen MT
    Cornea; 2007 Sep; 26(8):949-52. PubMed ID: 17721294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive, objective, multimodal tear dynamics evaluation of 5 over-the-counter tear drops in a randomized controlled trial.
    Tung CI; Kottaiyan R; Koh S; Wang Q; Yoon G; Zavislan JM; Davio SR; Aquavella JV
    Cornea; 2012 Feb; 31(2):108-14. PubMed ID: 22138585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence of Corneal Staining after Cataract Surgery with and without Chitosan-N-Acetylcysteine Eye Drops.
    Palkovits S; Schlatter A; Ruiss M; Georgiev S; Zeilinger J; Pilwachs C; Findl O
    Ophthalmic Res; 2023; 66(1):1293-1299. PubMed ID: 37797590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of two artificial tear formulations for dry eye through high-resolution optical coherence tomography.
    Garcia-Lázaro S; Belda-Salmerón L; Ferrer-Blasco T; Cerviño A; Montés-Micó R
    Clin Exp Optom; 2011 Nov; 94(6):549-56. PubMed ID: 21929716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Tear Meniscus Dynamics Using Anterior Segment Swept-Source Optical Coherence Tomography After Topical Solution Instillation for Dry Eye.
    Akiyama-Fukuda R; Usui T; Yoshida T; Yamagami S
    Cornea; 2016 May; 35(5):654-8. PubMed ID: 26989953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy in patients with dry eye after treatment with a new lubricant eye drop formulation.
    Davitt WF; Bloomenstein M; Christensen M; Martin AE
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):347-53. PubMed ID: 20653478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.